AKT1 and prostate cancer: Upregulation of FOXO3a and Par-4 were seen in WA-treated tumors, suggesting abolition of AKT-mediated signaling and reversion of the pro-apoptotic function of the FOXO3a and Par-4 signaling axis in prostate cancer (Figure 6).